Organon & Co. (OGN) stock
Close on Nov 11, 2026Market cap $3.65BP/E 18.0Yield 2.45%
Organon & Co. saw revenue fall 3.2% to $6.10B over the twelve months to Sep 30, 2026. Free cash flow was $675.00M, down 13.1% from a year earlier. At the latest close the market valued the company at $3.65B, 18.0 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $3.65B
- P/E ratio
- 18.0
- Price to sales
- 0.60
- Price to book
- 3.06
- Dividend yield
- 2.45%
- Free cash flow yield
- 18.50%
Fundamentals
- Revenue
- $6.10B
- Net income
- $213.00M
- EPS, diluted
- $0.77
- Free cash flow
- $675.00M
- Book value per share
- $4.38
- Diluted shares
- 272M
Trading
- Previous close
- $13.89
- Open
- $13.89
- Day's range
- $13.86 – $13.89
- Volume
- 1,870,559
- Average volume (20 days)
- 2,544,845
- Index membership
- S&P SmallCap 600 (since Nov 2023), Russell 1000 (since Jun 2021), Russell 3000 (since Aug 2021)
- Beta (5 years)
- 0.82
- 52-week range
- $5.69 – $13.89
- RSI (14 days)
- 64.7
- Volatility (1 year)
- 58.2%
- Relative volume
- 0.71×
- WACC
- 5.1%
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | OGN | S&P 500 | Difference | OGN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +0.6% | -2.4% | +3.0 pts | ||
| 3 months | +1.9% | -1.2% | +3.1 pts | ||
| Year to date | +94.8% | +12.3% | +82.5 pts | ||
| 1 year | +86.2% | +12.4% | +73.8 pts | ||
| 3 years | +36.8% | +78.8% | −42.0 pts | +11.0% | +21.4% |
| 5 years | -51.2% | +75.2% | −126.4 pts | -13.4% | +11.9% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Net income
EPS, diluted
Free cash flow
Press releases
Releases Organon filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Results
- Update
- Results
- Results
About Organon
Pharmaceutical Preparations
Organon & Co. is a healthcare company that develops and supplies pharmaceutical treatments centered on women’s health and general medicine. Its business is organized into women’s health, biosimilars, and established brands. The women’s health segment focuses on prescription contraception and fertility treatments, including implants, vaginal rings, and follicle-stimulating injections. Its biosimilar offerings treat immunology and oncology conditions, while the established brands portfolio covers cardiovascular, respiratory, dermatology, bone health, and non-opioid pain medications. Organon distributes its products to drug wholesalers, retailers, hospitals, government agencies, and managed care institutions such as pharmacy benefit managers and health maintenance organizations.
Company profile, executives and historyOrganon stock: common questions
What is Organon's stock price?
OGN closed at $13.89 on Nov 11, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $5.69 and $13.89.
What is Organon's market cap?
Organon was worth $3.65B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is OGN's P/E ratio?
OGN trades at 18.0 times earnings, based on diluted earnings per share of $0.77 over the twelve months to Sep 30, 2026.
How much revenue does Organon make?
Organon reported revenue of $6.10B for the twelve months to Sep 30, 2026, down 3.2% from a year earlier.
Does Organon pay a dividend?
Yes. Organon paid $0.34 per share over the last twelve months, a yield of 2.45% at the latest price.
How has OGN stock performed over the past year?
Including dividends, OGN returned +86.2% over the past year, against +12.4% for the S&P 500.
How many OGN shares are sold short?
20M shares were sold short at the latest FINRA report, 7.53% of the float, or 8.5 days of average trading volume.
Who are Organon's competitors?
Companies most similar to Organon by business, industry and size include GRFS, VTRS, PRGO, ONC, AMRX.
See a number that looks wrong?